At Sandoz, we discover new ways to improve and extend people’s lives. We pioneer novel approaches to help people around the world access high-quality medicine. To achieve this, we pursue an integrated access strategy that focuses our work on improving access to medicines, access to medical information and access to medical capacity building, which includes efforts to provide and support appropriate training for healthcare professionals. In 2015, our products reached an estimated 520 million patients and our aspiration is to reach 1 billion people.
At least 400 million people worldwide cannot access essential health services and more than 2 billion cannot afford to buy the medicines they need.
In addition to the leading rankings in biosimilars and generic antibiotics, dermatology and transplantation medicines, Sandoz has a very strong presence in areas ranging from generic cardiovascular, central nervous system (CNS), pain and ophthalmology to oncology, respiratory and hormonal therapeutics. Our broad portfolio is backed by a range of state-of-the-art technologies, formulations and devices, including prolonged-release and multiple-unit tablets, creams and gels, orodispersible films, transdermal patches, lyophilized products, implants and inhalers. We have strong scientific roots that have driven many medical innovations, from the first oral penicillin in 1951 to the first biosimilars in Europe and the US. We go beyond providing standard products and add value to the healthcare system through a range of support services and value-added medicines including combination formulations.
Sandoz: Increasing access to high-quality healthcare
Job Number: UK/MKT/SDZ/17-0059 Date of preparation: 21st April 2017